Ceftazidime/avibactam for the treatment of bloodstream infection due to carbapenemase-producing Enterobacterales in onco-haematologic neutropenic patients (the TARZAN study)
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf120 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Enric Sastre-Escolà und 20 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospital…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacteremia, Carbapenem-Resistant Enterobacteriaceae, Ceftazidime. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Pfizer International, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Objectives
To assess the clinical features, antibiotic therapy and outcomes of carbapenemase-producing Enterobacterales bloodstream infection (CPE-BSI) in neutropenic patients with haematological malignancies treated with ceftazidime/avibactam.
Methods
We conducted a multicentre, international, retrospective, descriptive study of CPE-BSI episodes in neutropenic onco-haematological patients treated with ceftazidime/avibactam as empirical and/or targeted therapy (2017–2022).
Results
Of 54 episodes of CPE-BSI in haematological patients with neutropenia, more than half presented acute myeloid leukaemia (32, 59.5%). Klebsiella pneumoniae was the most frequently isolated pathogen (79.5%) and KPC the most prevalent carbapenemase (52%). The source of BSI was mainly endogenous (57.5%). Up to 11% presented with septic shock. Initial empirical antibiotic therapy was inadequate in 47% of cases, particularly monotherapy with meropenem or piperacillin/tazobactam. Ceftazidime/avibactam was administered empirically in 30% of patients and targeted in all episodes, mainly in combination with aminoglycosides, colistin or tigecycline. Nephrotoxicity occurred in 15% of patients, being attributed to aminoglycosides or colistin. Intensive care unit admission was required in 20% of cases. All-cause 7-day and 30-day case-fatality rates were 11% and 24%, respectively. Multivariate analysis showed that septic shock at BSI onset was an independent risk factor for 30-day mortality.
Conclusions
Ceftazidime/avibactam proved to be safe and efficacious for the treatment of CPE-BSI in this extremely high-risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
- First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
- Clinic of Infectious Diseases, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Infectious Diseases Department, Hospital Ramón y Cajal, Madrid, Spain.
- Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
ORCID-Profile: Malgorzata Mikulska, Adaia Albasanz-Puig, Marina Machado, Nikolaos V Sipsas, Jesús Fortún, Ana Fernández-Cruz, Jordi Carratalà
Förderung
- Pfizer International
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas
- Instituto de Salud Carlos III
- Instituto de Salud Carlos III, Madrid, Spain
Zitieren
APA
Sastre-Escolà, E., Ntziora, F., Chiurlo, M., Martín-Dávila, P., Mikulska, M., Albasanz-Puig, A., Machado, M., Gutiérrez-Villanueva, A., Márquez-Gómez, I., Gasch-Blasi, O., Sipsas, N. V., Oltolini, C., Fortún, J., Ruiz-Camps, I., Fernández-Cruz, A., Peña, M., Laporte-Amargos, J., Bergas, A., Badia-Tejero, A. M., …, & Gudiol, C. (2025). Ceftazidime/avibactam for the treatment of bloodstream infection due to carbapenemase-producing Enterobacterales in onco-haematologic neutropenic patients (the TARZAN study). Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf120
Vancouver
Sastre-Escolà E, Ntziora F, Chiurlo M, Martín-Dávila P, Mikulska M, Albasanz-Puig A, et al. Ceftazidime/avibactam for the treatment of bloodstream infection due to carbapenemase-producing Enterobacterales in onco-haematologic neutropenic patients (the TARZAN study). Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf120
BibTeX
@article{SastreEscol2025,
author = {Sastre-Escolà, Enric and Ntziora, Fotinie and Chiurlo, Matteo and Martín-Dávila, Pilar and Mikulska, Malgorzata and Albasanz-Puig, Adaia and Machado, Marina and Gutiérrez-Villanueva, Andrea and Márquez-Gómez, Ignacio and Gasch-Blasi, Oriol and Sipsas, Nikolaos V and Oltolini, Chiara and Fortún, Jesús and Ruiz-Camps, Isabel and Fernández-Cruz, Ana and Peña, Marta and Laporte-Amargos, Julia and Bergas, Alba and Badia-Tejero, Ana Maria and Carratalà, Jordi and Gudiol, Carlota},
title = {Ceftazidime/avibactam for the treatment of bloodstream infection due to carbapenemase-producing Enterobacterales in onco-haematologic neutropenic patients (the TARZAN study)},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf120}
}
EUVIMED